| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 50.96 | 151.7% |
| Total Income | 50.96 | 151.7% |
| Expenditure | 71.22 | 24.6% |
| PBT | -28.35 | 34.8% |
| Net Profit | -23.57 | 46.2% |
| OPM | -39.76% | |
| NPM | -46.26% | |
| EPS | -0.47 | 48.9% |
UroGen Reports Q1 2026 ZUSDURI Revenue More Than Doubled Q-o-Q
06 May 2026 · 6 May, 5:37 pm
Summary
UroGen Pharma Ltd. announced financial results for the first quarter ended March 31, 2026. Total revenue was $51.0 million, a 152% increase compared to $20.3 million in Q1 2025, driven by the commercial launch of ZUSDURI and JELMYTO revenue growth. ZUSDURI generated $29.2 million in revenue, representing 109% quarter-over-quarter growth, while JELMYTO achieved $21.7 million in revenue, a 7% year-over-year increase. The company reported a net loss of $23.6 million, an improvement from the $43.8 million net loss in the same period last year. UroGen continues to expect 2026 net product revenue for JELMYTO to be in the range of $97 million to $101 million.
Key Highlights
- 1
ZUSDURI generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth.
- 2
JELMYTO achieved $21.7 million in revenue in Q1 2026, representing year-over-year growth of 7%.
- 3
Total revenue was $51.0 million in the first quarter ended March 31, 2026, compared with $20.3 million in the first quarter of 2025.
- 4
UroGen plans to submit a New Drug Application (NDA) for UGN-103 in the second half of 2026.
- 5
UroGen reported a net loss of $23.6 million or ($0.47) per basic and diluted share in the quarter ended March 31, 2026, compared with a net loss of $43.8 million in the first quarter of 2025.
- 6
As of March 31, 2026, cash, cash equivalents and marketable securities totaled $140.3 million.
- 7
The Company continues to expect 2026 net product revenue for JELMYTO to be in the range of $97 million to $101 million.
Management Comments
Liz Barrett
2026 is off to a strong start, with expanding usage of ZUSDURI™ (mitomycin) for intravesical solution and clear acceleration across key commercial indicators, including prescriber trial and adoption. These trends reflect growing clinical confidence in ZUSDURI as a primary, non-surgical therapy for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The early launch momentum is now translating into meaningful revenue growth, providing early validation of our commercial model and reinforcing the blockbuster potential for ZUSDURI. In parallel, we continue to advance our broader pipeline, including next generation products UGN-103 in LG-IR-NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma (LG-UTUC), as well as UGN-501, our investigational, potentially best-in-class, next-generation oncolytic virus. With this momentum, we are well positioned to execute our long-term growth strategy and continue to expand our leadership position in uro-oncology.
Informational and educational content only. Not investment advice.